Table 1 Patient characteristics

From: Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity

Age (years), median, range

5.0 (0.22–14)

Weight (kg), median, range

17.8 (4.4–80)

Sex, male/female

19/12

Diagnosis

 

 Acute leukemias

4

 Other malignanciesa

14

 Nonmalignant hematologic diseasesb

5

 Immunodeficienciesc

4

 Other inborn errorsd

4

Donor type

 

 Matched family

6

 Mismatched related family

4

 Matched unrelated

21

Conditioning e

 

 Bu, Cy

11

 Bu, Mel, Cy

15

 Bu, Cy, Eto

2

 Bu, Cy, Flu

3

  1. aMyelodysplastic syndrome (n=10), Ph' chronic myeloid leukemia (n=1), juvenile myelomonocytic leukemia (n=3).
  2. bThalassemia (n=2), idiopathic aplastic anemia (n=1), amegakaryocytosis (n=1), Shwachmann syndrome (n=1).
  3. cSevere combined immunodeficiency (n=1), hemophagocytic disorders (n=3).
  4. dOsteopetrosis (n=2), leukodystrophies (n=2).
  5. eBu=intravenous busulfan; Cy=cyclophosphamide; Mel=melphalan; Eto=etoposide; Flu=fludarabine (for dosages, see text).
Back to article page